Industries > Pharma > Global Next-Generation Antibody Therapies Market Forecast 2017-2027

Global Next-Generation Antibody Therapies Market Forecast 2017-2027

Antibody-Drug Conjugates (ADC), Biosimilar Antibodies, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments and Antibody-Like Proteins (ALPs)

PUBLISHED: 25 May 2017
PAGES: 249
PRODUCT CODE: PHA0195

Clear
WOOCS 2.2.1

The global next-generation antibody therapies market is expected to grow at a CAGR of 35.9% in the first half of the forecast period. The market is expected to grow at a CAGR of 22.4% from 2016-2027. The market is estimated at $3.1bn in 2016 and $14.1bn in 2021.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 249-page report you will receive 133 charts – all unavailable elsewhere.

The 249-page report provides clear detailed insight into the global next-generation antibody therapies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Global Next-Generation Antibody Therapies Market forecasts from 2017-2027

• Along with revenue prediction for the overall world market for next-generation antibody therapies, our investigation shows forecasts to 2027 for the following five submarkets:
– Antibody-drug conjugates (ADCs)
– Engineered antibodies
– Bispecific antibodies
– Antibody fragments and antibody-like proteins (ALPs)
– Biosimilar antibody therapies

• How will leading next-generation antibody therapies perform to 2027 at world level? Our study forecasts individual revenues of seven products:
– Adcetris
– Kadcyla
– Gazyva/Gazyvaro
– Poteligeo
– Removab
– Blincyto
– Kalbitor

• Our analyses show individual revenue forecasts to 2027 for these regional markets:
– US
– EU5 group
– Asia-Pacific region
– Latin America
– Rest of the World

Global Next-Generation Antibody Therapies Market Forecast 2017-2027

• This report discusses issues affecting the next-generation antibody therapies market:
– R&D for next generation antibodies – explore technologies and potentials
– Challenges with current monoclonal antibody (mAb) therapies
– Big pharma companies investing in next-generation antibody research and development
– Biosimilars and their effects on the next-generation antibody therapies market

• Our study discusses strengths, weaknesses, opportunities and threats as well as social, technological, economic and political factors that affect the next-generation antibody therapies market

Visiongain’s study is intended for anyone requiring commercial analyses for the next-generation antibody therapies market. You find data, trends and predictions.

Buy our report today Global Next-Generation Antibody Therapies Market Forecast 2017-2027: Antibody-Drug Conjugates (ADC), Biosimilar Antibodies, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments and Antibody-Like Proteins (ALPs).

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Next-Generation Antibody Therapies Market Forecast 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Global Next-Generation Antibody Therapies Market Forecast 2017-2027


Latest Pharma news

Visiongain Publishes Cancer Diagnostics Market Report 2021-2031

Major investments have been made by companies in the cancer diagnostics industry in the past few years to develop novel tests to capitalize on the opportunities in the untapped market.

19 April 2021

READ

Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030

The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.

12 April 2021

READ

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

READ

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

READ

Categories